The Latest Breaking News from Moderna

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine. The booster raised virus-neutralizing antibodies by eight-fold in a study.

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

In mid-June, the World Trade Organization (WTO) will meet to finish negotiations to waive certain sections of the agreement on Trade Related Intellectual Property Rights (TRIPS). However, it is not the TRIPS waiver originally proposed 18 months ago by member states South Africa and India, which would have allowed countries…

Social media users shared a range of false claims this week

Children under five represent the only age group yet to have a vaccine approved for use

Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results…

A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc's COVID-19 vaccine.

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.